NK cell-triggered CCL5/IFNg-CXCL9/10 axis underlies the clinical efficacy of HER2-targeted antibodies in primary HER2-positive breast cancer. NK cell-triggered CCL5/IFNg-CXCL9/10 axis underlies the clinical efficacy of HER2-targeted antibodies in primary HER2-positive breast cancer
收藏NIAID Data Ecosystem2026-05-01 收录
下载链接：
https://www.ncbi.nlm.nih.gov/bioproject/PRJNA961722
下载链接
链接失效反馈官方服务：
资源简介：
This SuperSeries is composed of the SubSeries listed below. Overall design: Refer to individual Series
创建时间：
2023-04-25
